Use of granisetron transdermal system in the prevention of chemotherapy-induced nausea and vomiting: a review.

Authors:
Tuca A.

Journal:
Cancer Manag Res

Publication Year: 2009

PMCID:
PMC3004574

PMID:
21188092

View on PubMed View on PMC
Journal Information

Full Title: Cancer Manag Res

Abbreviation: Cancer Manag Res

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Oncology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Correlation Between DCAMKL-1 Protein Expression and K-ras Gene Mutation in Colorectal Cancer.
Wu X; Li S; Yang Y and 2 more (2024) - Transparency Score: 3/6
Feasibility and Tolerability of Anlotinib Plus PD-1 Blockades for Patients with Treatment-Refractor…
Bai H; Wang WH; Zhou FF and 2 more (2024) - Transparency Score: 3/6
High Expression of WT1 and Low Expression of p53 in Archived Blocks of Children with Wilms Tumor in…
Ssenkumba B; Atwiine B; Mitala Y and 5 more (2024) - Transparency Score: 3/6
Resumption of Intravenous Anti-Cancer Therapy in Breast Cancer: A Real-World Experience During the …
Yang F; Li C; Qiu Y and 7 more (2024) - Transparency Score: 3/6
ZNF217: An Oncogenic Transcription Factor and Potential Therapeutic Target for Multiple Human Cance…
Wang Y; Ma C; Yang X and 2 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosure: The author has no involvement in the pharmaceutical company that has developed the granisetron transdermal delivery system, nor has he received any funding to support the preparation of this paper, which is based only on available literature. The author declares no involvement that can be construed as a conflict of interest."

Evidence found in paper:

"Disclosure: The author has no involvement in the pharmaceutical company that has developed the granisetron transdermal delivery system, nor has he received any funding to support the preparation of this paper, which is based only on available literature. The author declares no involvement that can be construed as a conflict of interest."

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025